long intergenic non-protein coding RNA 1215Genealiases: []
Q-omics provides the consensus-scored LINC01215 profile across patient tissues and cancer cell-line models. LINC01215 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01215 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, LINC01215 RNA expression shows 14,975 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, BLCA, and DLBC as cancer lineages where LINC01215 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01215 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01215 survival associations across molecular data types. LINC01215 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01215 RNA expression–survival associations across cancer types. High LINC01215 expression shows unfavorable associations in LGG, but favorable associations in HNSC, LUAD, SKCM, READ and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01215 RNA expression.
This table summarizes LINC01215 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01215. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01215 shows lower tumor expression in BLCA, COAD and KICH and higher tumor expression in BRCA, KIRC and THCA. The BLCA box plot shows higher LINC01215 RNA expression in normal versus tumor tissue (log2 FC = −0.564, t-test p = .003).
This table shows molecular features associated with LINC01215 in patient tissues and cancer cell lines. In patient samples, LINC01215 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
